Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope Share
CLICK HERE TO SHARE YOUR STORY!
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
Menu
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
  • Join PW

Daily Archives: June 14, 2021

  1. Home>
  2. 2021>
  3. June>
  4. 14
Research Program Formed to Develop Ewing Sarcoma Immunotherapy
source: pixabay.com

Research Program Formed to Develop Ewing Sarcoma Immunotherapy

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:Ewing's family of tumors

In a press release from late May 2021, biotechnology company CancerVAX, Inc. ("CancerVAX"), which works to develop targeted immunotherapy treatments, shared that it had entered into a sponsored research agreement…

Continue Reading Research Program Formed to Develop Ewing Sarcoma Immunotherapy
Iptacopan for IgAN Meets Phase 2 Trial Primary Endpoint
source: pixabay.com

Iptacopan for IgAN Meets Phase 2 Trial Primary Endpoint

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:IgA Nephropathy/IgA Nephropathy (IgAN)

From June 5-8, 2021, the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) held its 58th Annual Congress. Though the event was held virtually, the meeting still expanded…

Continue Reading Iptacopan for IgAN Meets Phase 2 Trial Primary Endpoint
Study of the Week: Some Genetic Tests Miss Familial Hypercholesterolemia
source: pixabay.com

Study of the Week: Some Genetic Tests Miss Familial Hypercholesterolemia

  • Post author:James Moore
  • Post published:June 14, 2021
  • Post category:Familial Hypercholesterolemia

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Some Genetic Tests Miss Familial Hypercholesterolemia
Positive Topline Data Available on Itolizumab for GvHD
rawpixel / Pixabay

Positive Topline Data Available on Itolizumab for GvHD

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:Graft versus Host Disease

According to a June 11 press release from biotechnology company Equillium, Inc. ("Equillium"), positive topline data is now available from the Phase 1b EQUATE clinical trial. Within the clinical trial,…

Continue Reading Positive Topline Data Available on Itolizumab for GvHD
This Gene Therapy Uses Tylenol to Treat PKU and Hemophilia
mcmurryjulie / Pixabay

This Gene Therapy Uses Tylenol to Treat PKU and Hemophilia

  • Post author:Kendall Mason
  • Post published:June 14, 2021
  • Post category:Hemophilia/Phenylketonuria/pku

Gene therapies are becoming an increasingly popular treatment for genetic diseases, especially rare ones. Now, medical professionals are trying a new strategy with gene therapy: adding acetaminophen, also known by…

Continue Reading This Gene Therapy Uses Tylenol to Treat PKU and Hemophilia
New Safety and Tolerability Data Available on CAEL-101 for AL Amyloidosis
source: pixabay.com

New Safety and Tolerability Data Available on CAEL-101 for AL Amyloidosis

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:Amyloidosis

Currently, the European Hematology Association (EHA) Virtual Congress 2021 is going on from June 9 through 17, 2021. During the Congress, hematologists and other stakeholders will discuss clinical research and…

Continue Reading New Safety and Tolerability Data Available on CAEL-101 for AL Amyloidosis
New Data Available on Oxbryta for SCD
source: pixabay.com

New Data Available on Oxbryta for SCD

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:Sickle Cell Disease

Currently, the European Hematology Association (EHA) is holding its 2021 Virtual Congress through June 17, 2021. During the event, researchers are expounding on new insights and research within the hematological…

Continue Reading New Data Available on Oxbryta for SCD
PREVNAR 20 for Multiple IPD Serotypes Now FDA-Approved
ulleo / Pixabay

PREVNAR 20 for Multiple IPD Serotypes Now FDA-Approved

  • Post author:Jessica Lynn
  • Post published:June 14, 2021
  • Post category:Invasive pneumococcal disease

On June 8, 2021, pharmaceutical and biotechnology company Pfizer Inc. ("Pfizer") shared that its Pneumococcal 20-valent Conjugate Vaccine (PREVNAR 20) is now FDA-approved. The vaccine helps protect against 20 different…

Continue Reading PREVNAR 20 for Multiple IPD Serotypes Now FDA-Approved
All About the Changes to Beovu’s Safety Label
https://unsplash.com/photos/In4XVKhYaiI

All About the Changes to Beovu’s Safety Label

  • Post author:Kendall Mason
  • Post published:June 14, 2021
  • Post category:Wet macular degeneration

The FDA approved Beovu, a treatment for wet age-related macular degeneration (wAMD), back in October of 2019. Now, not even two years later, there are changes that must be made…

Continue Reading All About the Changes to Beovu’s Safety Label

Featured


Picture of Family


Metastatic Breast Cancer: Navigating Grief


Picture of Ralph Family walking


Rethinking What It Means to Live With Acromegaly


Illustration of mentor program members


The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

CLICK HERE TO SHARE YOUR STORY!
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Notice
Privacy Policy for CA Residents
EU/UK Privacy Notice
Data Privacy Framework: Consumer Privacy Policy
Consumer Health Data Privacy Policy
Cookie Notice

Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope

© Copyright 2024 Patient Worthy

Sign Up With a Patient Worthy Account and Share Your Rare Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info

We're Happy You're Here!

What best describes you when it comes to rare disease? (check all that apply)

What rare disease(s)/conditions are most important to you?

Visit Home Page or

Thank you for signing up for a Patient Worthy Account!

Have a rare disease story to share? Let us know

Share Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info